anti-infective drugs
Phase 3Small molecule
anti-infective drugs is one of 53 small molecule programs targeting Infectious Disease. It is currently in Phase 3.
2
Indications
4
Total Trials
3
Active Trials
52
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
55 competitors in Children
#DrugCompanyPhaseTrials
1Promacta
GSKApproved
Gleevec
NovartisApproved
Oncaspar
SServier
Approved
Velcade
SShilpa Grover, MD, MPH
Approved
Sprycel
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Approved
Byetta
AstraZenecaPhase 3
Neurontin
VViatris Specialty LLC
Phase 3
Somavaratan
Novo NordiskPhase 3
Veklury
GileadPhase 2
Xyrem
Jazz PharmaceuticalsPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Infectious Disease1 trial
Population Pharmacokinetics of Meropenem and Linezolid in Children With Severe Infectious Diseases
Unknown status·—··NCT03643497·800 enrolled
Infections1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for anti-infective drugs. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- SShandong University